156 related articles for article (PubMed ID: 14727248)
1. Ongoing prospective multicenter safety study of the cytoprotectant amifostine given subcutaneously: overview of trial design.
Samuels MA; Chico IM; Hirsch RL; Fullmer K;
Semin Oncol; 2003 Dec; 30(6 Suppl 18):94-5. PubMed ID: 14727248
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and efficacy of subcutaneous amifostine therapy in patients with head and neck cancer treated with curative accelerated concomitant-boost radiation therapy.
Ozsahin M; Betz M; Matzinger O; Bron L; Luthi F; Pasche P; Azria D; Mirimanoff RO; Zouhair A
Arch Otolaryngol Head Neck Surg; 2006 Feb; 132(2):141-5. PubMed ID: 16490870
[TBL] [Abstract][Full Text] [Related]
3. Effects of dose and schedule on the efficacy of ethyol: preclinical studies.
Cassatt DR; Fazenbaker CA; Kifle G; Bachy CM
Semin Oncol; 2003 Dec; 30(6 Suppl 18):31-9. PubMed ID: 14727238
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of subcutaneous amifostine and radiation therapy in patients with head and neck cancer.
Anné PR; Curran WJ
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):18-9. PubMed ID: 11917279
[TBL] [Abstract][Full Text] [Related]
5. Clinical trial of endorectal amifostine for radioprotection in patients with prostate cancer: rationale and early results.
Ménard C; Camphausen K; Muanza T; Sears-Crouse N; Smith S; Ben-Josef E; Coleman CN
Semin Oncol; 2003 Dec; 30(6 Suppl 18):63-7. PubMed ID: 14727242
[TBL] [Abstract][Full Text] [Related]
6. Reduction of treatment breaks and radiation-induced esophagitis and pneumonitis using amifostine in unresectable non-small cell lung cancer patients receiving definitive concurrent chemotherapy and radiation therapy: a prospective community-based clinical trial.
Wynn RB; Mehta V
Semin Oncol; 2005 Apr; 32(2 Suppl 3):S99-104. PubMed ID: 16015543
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancer.
Anné PR
Semin Oncol; 2002 Dec; 29(6 Suppl 19):80-3. PubMed ID: 12577250
[TBL] [Abstract][Full Text] [Related]
8. Feasibility of amifostine administration in conjunction with high-dose rate brachytherapy.
Dziuk T; Senzer N
Semin Oncol; 2003 Dec; 30(6 Suppl 18):49-57. PubMed ID: 14727240
[TBL] [Abstract][Full Text] [Related]
9. Rationale for integrating high-dose rate intraoperative radiation (HDR-IORT) and postoperative external beam radiation with subcutaneous amifostine for the management of stage III/IV head and neck cancer.
Hu K; Ship JA; Harrison LB
Semin Oncol; 2003 Dec; 30(6 Suppl 18):40-8. PubMed ID: 14727239
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of subcutaneous amifostine in minimizing radiation-induced toxicities in patients receiving combined-modality treatment for squamous cell carcinoma of the head and neck.
Law A; Kennedy T; Pellitteri P; Wood C; Christie D; Yumen O
Int J Radiat Oncol Biol Phys; 2007 Dec; 69(5):1361-8. PubMed ID: 17869022
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of subcutaneous amifostine in patients undergoing postoperative intensity modulated radiation therapy for head and neck cancer: preliminary data.
Thorstad WL; Haughey B; Chao KS
Semin Oncol; 2003 Dec; 30(6 Suppl 18):96-100. PubMed ID: 14727249
[TBL] [Abstract][Full Text] [Related]
12. Improved tolerability of amifostine with rapid infusion and optimal patient preparation.
Boccia R
Semin Oncol; 2002 Dec; 29(6 Suppl 19):9-13. PubMed ID: 12577237
[TBL] [Abstract][Full Text] [Related]
13. Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer.
Antonadou D; Petridis A; Synodinou M; Throuvalas N; Bolanos N; Veslemes M; Sagriotis A
Semin Oncol; 2003 Dec; 30(6 Suppl 18):2-9. PubMed ID: 14727235
[TBL] [Abstract][Full Text] [Related]
14. Open label multicenter trial of subcutaneous amifostine (Ethyol) in the prevention of radiation induced esophagitis and pneumonitis in patients with measurable, unresectable non-small cell lung cancer.
Mehta V
Semin Oncol; 2004 Dec; 31(6 Suppl 18):42-6. PubMed ID: 15726522
[TBL] [Abstract][Full Text] [Related]
15. Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy.
Bardet E; Martin L; Calais G; Tuchais C; Bourhis J; Rhein B; Feham N; Alphonsi M
Semin Oncol; 2002 Dec; 29(6 Suppl 19):57-60. PubMed ID: 12577246
[TBL] [Abstract][Full Text] [Related]
16. Aggressive multimodality therapy for patients with locally advanced esophageal cancer: is there a role for amifostine?
Jatoi A
Semin Oncol; 2003 Dec; 30(6 Suppl 18):72-5. PubMed ID: 14727244
[TBL] [Abstract][Full Text] [Related]
17. Amifostine and external beam radiation therapy and/or high-dose rate brachytherapy in the treatment of localized prostate carcinoma: preliminary results of a phase II trial.
Linares LA; Echols D
Semin Oncol; 2003 Dec; 30(6 Suppl 18):58-62. PubMed ID: 14727241
[TBL] [Abstract][Full Text] [Related]
18. Toxicity profile of intensity-modulated radiation therapy for head and neck carcinoma and potential role of amifostine.
Chao KS; Ozyigit G; Thorsdad WL
Semin Oncol; 2003 Dec; 30(6 Suppl 18):101-8. PubMed ID: 14727250
[TBL] [Abstract][Full Text] [Related]
19. Preclinical modeling of improved amifostine (Ethyol) use in radiation therapy.
Cassatt DR; Fazenbaker CA; Bachy CM; Hanson MS
Semin Radiat Oncol; 2002 Jan; 12(1 Suppl 1):97-102. PubMed ID: 11917293
[TBL] [Abstract][Full Text] [Related]
20. Subcutaneous administration of amifostine during fractionated radiotherapy: a randomized phase II study.
Koukourakis MI; Kyrias G; Kakolyris S; Kouroussis C; Frangiadaki C; Giatromanolaki A; Retalis G; Georgoulias V
J Clin Oncol; 2000 Jun; 18(11):2226-33. PubMed ID: 10829042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
